Clinical trials: RhA - Rheumatoid Arthritis
Rheumatoid Arthritis, NOS
PoC in Rheumatoid Arthritis With Methotrexate
The purpose of this study is to find out if 300 mg of BMS-582949 given once daily will be more effective than placebo after 12 weeks of treatment in subjects with rheumatoid arthritis who are also taking methotrexate
- Trial name
- NCT00605735
- Testing
- BMS-582949
- Where
- 28 sites in United States, Argentina and 6 more
- Volunteers
- 121 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)
This study will assess the long-term safety and efficacy of repeat treatment courses of rituximab, in combination with methotrexate in a disease-modifying anti-rheumatic drug (DMARD) inadequate responder population of…
- Trial name
- NCT02093026
- Testing
- Rituximab, Methotrexate, Methylprednisolone
- Where
- 92 sites in United States, Australia and 14 more
- Volunteers
- 465 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Follow-up of Rheumatoid Arthritis (RA) Moderate to Low Disease Activity Study
To continue to assess the clinical safety and efficacy of Certolizumab Pegol as add-on therapy with stable-dose Disease Modifying Anti-Rheumatic Drugs (DMARDs)
- Trial name
- CERTAIN 2 (NCT00843778)
- Testing
- Certolizumab Pegol
- Where
- 25 sites in Austria, France and 3 more
- Volunteers
- 131 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy
This is a randomized, double-blind, placebo-controlled, Phase 2 study to evaluate the safety and efficacy of CCX354-C in subjects with rheumatoid arthritis partially responsive to methotrexate therapy.
- Trial name
- CARAT-2 (NCT01242917)
- Testing
- CCX-354-C, CCX354-C
- Where
- 41 sites in Belgium, Czechia and 6 more
- Volunteers
- 159 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis
- Trial name
- ADMYRA (NCT02744755)
- Testing
- Adalimumab - GP2017, Adalimumab - US licensed Humira
- Where
- 83 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Sandoz
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Phase I Study of ICP-022 in Healthy Subjects
This is a single center, randomized, double-blind, placebo-controlled, dose escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ICP-022 following oral single and…
- Trial name
- NCT03189017
- Testing
- ICP-022
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Innocare Pharma Australia Pty Ltd
Rheumatoid Arthritis
The SPECTRA Study
The purpose of this study is to compare IL-1ra and the combination of IL-1ra and PEGsTNF-RI with respect to their ability to reduce inflammation and bone and cartilage destruction in the synovium of subjects with rheumatoid…
- Trial name
- NCT00537667
- Testing
- anakinra, anakinra and PEG sTNF-R1
- Volunteers
- 22 people
- Sponsor
- Amgen
Rheumatoid Arthritis
Phase 2 Clinical Study in Rheumatoid Arthritis With an Investigational Oral p38 MAP Kinase Inhibitor VX-702
The purpose of this study is to assess the clinical activity and safety of two doses of VX-702 compared to placebo in subjects with moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT00205478
- Testing
- VX-702
- Where
- 43 sites in Bulgaria, Croatia and 7 more
- Volunteers
- 300 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Arthritis, Rheumatoid
R-2487 in Patients With Rheumatoid Arthritis
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-2487) in patients with Rheumatoid Arthritis.
- Trial name
- R-2487-RA01 (NCT05961592)
- Testing
- R-2487 DP
- Where
- 6 sites in United States
- Volunteers
- 73 people
- Sponsor
- Rise Therapeutics LLC
Rheumatoid Arthritis
Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)
This extension study will evaluate the safety (including immunogenicity) of treatment with rituximab-Pfizer, as well as the safety and immunogenicity after transitioning from rituximab-US or rituximab-EU to rituximab-Pfizer.
- Trial name
- NCT01643928
- Testing
- Rituximab-Pfizer (PF-05280586) x 3 courses, Rituximab-EU+ Rituximab-Pfizer x 2 Courses, Rituximab-US + Rituximab-Pfizer x 2 Courses
- Where
- 71 sites in United States, Australia and 8 more
- Volunteers
- 185 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid
Safety and Efficacy of Meloxicam Compared to Other Nonsteroidal Antiinflammatory Drugs (NSAIDs) in an Observational Cohort Study of Patients With Rheumatoid Arthritis, Osteoarthritis, Lumbago, Scapulohumeral Periarthritis, Neck, Shoulder and Arm Syndrome
Study to assess the safety profile of meloxicam by comparing incidence of gastrointestinal adverse events of meloxicam with that of NSAID in the routine daily therapeutic situation.
- Trial name
- NCT02180516
- Testing
- Meloxicam, Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac
- Volunteers
- 9,984 people
- Sponsor
- Boehringer Ingelheim
Rheumatoid Arthritis, Osteoarthritis
Multi-Centre Study to Assess the Long-term Performance of the DePuy ASR™ System in Resurfacing and Primary Total Hip Replacement
The purpose of this study is to monitor the performance of a large metal-on-metal bearing from the DePuy ASR™ System in the treatment of patients with hip joint disease requiring hip resurfacing surgery or a total hip…
- Conditions
- Rheumatoid Arthritis, Osteoarthritis, Post-traumatic Arthritis, Collagen Disorders
- Trial name
- NCT00872547
- Testing
- DePuy ASR™ Hip System, DePuy ASR™ XL Head / ASR™ Acetabular Cup System
- Where
- 8 sites in Austria, Czechia and 6 more
- Volunteers
- 329 people
- Sponsor
- DePuy International
Rheumatoid Arthritis
Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis
The purpose of this study is to evaluate the safety and tolerability of multiple oral doses of CCX354-C at a number of dose levels in subjects with stable rheumatoid arthritis (RA).
- Trial name
- CARAT-1 (NCT01027728)
- Testing
- CCX 354-C
- Where
- 5 sites in Belgium, Romania
- Volunteers
- 24 people
- Sponsor
- Amgen
Rheumatoid Arthritis
A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice
This is a single-arm, open-label, non-randomized, multicenter trial to evaluate the efficacy and safety of using tocilizumab for confirmed rheumatoid arthritis participants in clinical practice.
- Trial name
- NCT02616328
- Testing
- No intervention
- Where
- 2 sites in Saudi Arabia
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
CAMEO: Canadian Methotrexate and Etanercept Outcome Study
The purpose of the study is to evaluate the use of etanercept in the treatment of rheumatoid arthritis with or without methotrexate treatment over a 24 month period
- Trial name
- NCT00654368
- Testing
- Etanercept, Methotrexate
- Where
- 28 sites in Canada
- Volunteers
- 258 people
- Sponsor
- Amgen
Rheumatoid Arthritis
ConsideRAte Study - Splenic Stimulation for RA
This study will evaluate the safety, tolerability, and effects of stimulating the splenic neurovascular bundle (NVB) with the Galvani System, which consists of a lead, implantable pulse generator, external components and…
- Trial name
- NCT05003310
- Testing
- Active Stimulation, Baricitinib, Background Treatment
- Where
- 14 sites in United States, Netherlands
- Volunteers
- 28 people
- Sponsor
- Galvani Bioelectronics
Systemic Juvenile Idiopathic Arthritis, Hereditary Periodic Fevers
A Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis or Hereditary Periodic Fevers Who Participated in the CACZ885G2301E1, CACZ885G2306 or CACZ885N2301 Studies
The objective of this extension protocol is to collect safety data (serious and non-serious adverse events) and to provide continuous canakinumab to patients in France who completed study CACZ885G2301E1(NCT00891046), CACZ885G2306…
- Trial name
- NCT02334748
- Testing
- canakinumab
- Where
- 3 sites in France
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Rheumatoid Arthritis
First-in-Human Single Ascending Dose of SHR0302
The purpose of the study is to evaluate the safety and tolerability of single ascending (SAD) oral doses of SHR0302 compared to placebo.
- Trial name
- NCT02423538
- Testing
- SHR0302
- Where
- China
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
Dose Ranging Study of ART621 in Subjects Diagnosed With Rheumatoid Arthritis Taking Methotrexate
The purpose of this clinical trial is to assess the safety, efficacy, tolerability, immunogenicity and pharmacokinetics of 3 dose levels of ART621 in the treatment of rheumatoid arthritis.
- Trial name
- NCT00928317
- Testing
- ART621
- Where
- 46 sites in United States, Argentina and 6 more
- Volunteers
- 13 people
- Sponsor
- Arana Therapeutics Ltd
Rheumatoid Arthritis
A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566
This is a single center randomized parallel-group partially-blinded, 4-arm Phase 1 study to evaluate the phototoxic potential of two dose levels of SAR441566 treatment compared to placebo and the active comparator, ciprofloxacin…
- Trial name
- NCT05844735
- Testing
- SAR441566, Ciprofloxacin
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.